Ratings Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Market Closed - Swiss Exchange 16:30:39 18/06/2024 BST 5-day change 1st Jan Change
274.6 CHF +1.18% Intraday chart for Roche Holding AG +3.47% +5.05%

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • The company's enterprise value to sales, at 3.46 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+5.05% 223B -
+52.93% 797B
C+
+40.55% 628B
B
-7.08% 351B
C+
+17.40% 323B
B-
+10.58% 300B
C+
+17.13% 244B
B+
+6.24% 163B
C+
-4.79% 153B
C+
-1.39% 118B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW